# US 2020/0138719 A1 · Tenofovir granules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138719 A1
- Document ID: US20200138719A1
- Status: Published application
- Kind: A1
- Application number: 16/735,143
- Filed: 2020-01-06
- Published: 2020-05-07
- Earliest claimed: 2017-01-27
- Assignees: Steerlife India Private Limited
- Applicants: Steerlife India Private Limited
- Inventors: Indu BHUSHAN; Vinay RAO; Radhika GHIKE
- Web page: https://patentgrep.com/patent/US20200138719A1

## CPC

- A61K 9/1688: {resulting in pure drug agglomerate optionally containing up to 5% of excipient}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a granular composition comprising essentially Tenofovir, wherein the composition is devoid of an excipient. Tenofovir granules of the present invention are prepared in twin-screw processor such that the content of total impurities in the prepared granules is less than 2.0%.

## Claims

### Claim 1

A process for preparing a granular composition consisting essentially of Tenofovir devoid of an excipient and with content of total impurities not more than 2.0% in twin screw processor comprising the steps of:
a. feeding Tenofovir into the intake zone of the twin screw processor;
b. conveying Tenofovir towards the kneading zone and processing it in the kneading zone;
c. conveying Tenofovir from the kneading zone towards the exit;
d. collecting the Tenofovir granules.

### Claim 2 (depends on 1)

The process for preparing granular composition of Tenofovir as claimed in claim 1 wherein the temperature of the barrel in the twin screw processor is between 25° C. and 60° C.

### Claim 3 (depends on 2)

The process for preparing granular composition of Tenofovir as claimed in claim 2 wherein the content of Tenofovir isoproxil monoester is not more than 1%; and wherein the content of Tenofovir disoproxil dimer is not more than 0.15%.

### Claim 4 (depends on 2)

The process for preparing granular composition of Tenofovir as claimed in claim 2 wherein the content of adenine is not more than 0.15%, the content of Tenofovir isoproxil monoester is not more than 1%, the content of Tenofovir disoproxil ethyl ester is not more than 0.15%, the content of Tenofovir isopropyl isoproxil is not more than 0.3%, the content of Tenofovir disoproxil carbamate is not more than 0.15% and the content of Tenofovir disoproxil dimer is not more than 0.15%.

### Claim 5 (depends on 1)

The process for preparing granular composition of Tenofovir as claimed in claim 1 wherein the said composition is stable after storage at 40° C. and 75% Relative Humidity for a period of at least 3 months.

### Claim 6 (depends on 1)

The process for preparing granular composition of Tenofovir as claimed in claim 1 wherein the said composition is stable after storage at 25° C. and 60% Relative Humidity for a period of at least 3 months.

### Claim 7 (depends on 1)

The process for preparing granular composition of Tenofovir as claimed in claim 1 wherein the said composition is stable after storage at 2° C. to 8° C. for a period of at least 3 months.
